SubsidieMeestersRevolutionary therapeutic treatment for stopping progression of Parkinson's disease
Herantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition.
Projectdetails
Introduction
Parkinson's disease (PD) is a common neurodegenerative disorder, affecting over 10 million people worldwide, of which 1.2 million are in the EU. This chronic disabling disease affects the central nervous system, causing severe motor and non-motor symptoms.
Economic Impact
The high disease burden for patients and their families also comes with a significant price tag for society, which is expected to increase dramatically with an ageing population. In the EU, the annual cost is currently 14 billion euros.
Pathology and Treatment
The causes of PD are unknown, and there is a broad spectrum of pathologies that ultimately lead to the loss of dopamine-producing neurons in the brain. The current dopamine substitution treatments alleviate some of the symptoms; however, there is no cure for PD nor any disease-modifying therapies.
Innovation by Herantis
Herantis has developed a new pharmaceutical, HER-096, with the ability to affect PD pathology and the potential to revolutionize the treatment of PD. This innovation aims to alleviate the huge burden that PD currently imposes on patients and healthcare systems.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.083.500 |
Tijdlijn
| Startdatum | 1-5-2023 |
| Einddatum | 30-4-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- HERANTIS PHARMA OYJpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions. | EIC Accelerator | € 1.636.639 | 2024 | Details |
Homeoproteins as novel therapies for neurodegenerative diseasesBrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function. | EIC Accelerator | € 2.500.000 | 2022 | Details |
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
Revolutionising the diagnosis of multiple Sclerosis with the first bioinformatic diagnostic kit that allows early detection with a simple blood testALA DIAGNOSTICS aims to revolutionize multiple sclerosis diagnosis with a fast, non-invasive blood test using a patented biomarker, reducing misdiagnoses and improving patient outcomes. | EIC Accelerator | € 1.407.525 | 2023 | Details |
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.
Homeoproteins as novel therapies for neurodegenerative diseases
BrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function.
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.
Revolutionising the diagnosis of multiple Sclerosis with the first bioinformatic diagnostic kit that allows early detection with a simple blood test
ALA DIAGNOSTICS aims to revolutionize multiple sclerosis diagnosis with a fast, non-invasive blood test using a patented biomarker, reducing misdiagnoses and improving patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel small molecule attenuator of neuroinflammation in Parkinson’s DiseaseNEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap. | ERC Proof of... | € 150.000 | 2025 | Details |
Unraveling Parkinson´s disease diagnosticUNMASK aims to validate a non-invasive, olfaction-inspired technology for fast Parkinson's disease diagnostics, addressing the need for timely detection and reducing its social and economic burden. | ERC Proof of... | € 150.000 | 2024 | Details |
Antilichaam voor Parkison behandelingAugmentor Management ontwikkelt een specifiek antilichaam tegen alphasynucleine oligomeren om de progressie van de ziekte van Parkinson te remmen en zoekt haalbaarheid voor verder onderzoek. | Mkb-innovati... | € 20.000 | 2021 | Details |
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative DiseaseThe project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens. | EIC Pathfinder | € 2.992.203 | 2022 | Details |
Parkinson in Motion; E-Health tool voor langer actief leven in de thuisomgevingHet project ontwikkelt de E-Health tool 'Parkinson-in-Motion' om mensen met Parkinson te ondersteunen in het behouden van een actieve levensstijl en het verbeteren van hun levenskwaliteit. | Mkb-innovati... | € 324.520 | 2022 | Details |
Novel small molecule attenuator of neuroinflammation in Parkinson’s Disease
NEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap.
Unraveling Parkinson´s disease diagnostic
UNMASK aims to validate a non-invasive, olfaction-inspired technology for fast Parkinson's disease diagnostics, addressing the need for timely detection and reducing its social and economic burden.
Antilichaam voor Parkison behandeling
Augmentor Management ontwikkelt een specifiek antilichaam tegen alphasynucleine oligomeren om de progressie van de ziekte van Parkinson te remmen en zoekt haalbaarheid voor verder onderzoek.
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease
The project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens.
Parkinson in Motion; E-Health tool voor langer actief leven in de thuisomgeving
Het project ontwikkelt de E-Health tool 'Parkinson-in-Motion' om mensen met Parkinson te ondersteunen in het behouden van een actieve levensstijl en het verbeteren van hun levenskwaliteit.